Search our team at AdventHealth Research Institute
-
NCT5812807
Optimice-PCR: De-Escalation Of Therapy In Early-Stage TNBC Patients Who Achieve PCR After Neoadjuvant Chemotherapy With Checkpoint Inhibitor Therapy
This study is currently enrolling.Associated Conditions: Breast CancerResearch Area: Clinical Cancer ResearchResearch Location: Orlando, FloridaThis study is being done to answer the following question: Among patients with early-stage TNBC who achieve a pCR after preoperative chemotherapy in combination with pembrolizumab, will observation...
-
NCT06072781
VS-6766-301/GOG-3097 A Phase 3, Randomized, Open-Label Study of Combination Therapy with Avutometinib plus Defactinib Versus Investigator’s Choice of Treatment in Patients with Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)
This study is currently enrolling.Associated Conditions: Ovarian, Fallopian, or Primary Peritoneum CancerResearch Area: Clinical Cancer ResearchResearch Location: Orlando, FloridaThe main aims of this clinical study are to: Find out if the combination of avutometinib (VS-6766) and defactinib is better at prolonging the time it takes for LGSOC to grow compared to standard of...
-
NCT05154487
GOG 3069 Phase 2 Study of Alpelisib and Fulvestrant for PIK3CA-mutated Estrogen Receptor (ER)-positive Endometrioid Endometrial Cancers
This study is currently enrolling.Associated Conditions: Endometrial CancerResearch Area: Clinical Cancer ResearchResearch Location: Orlando, FloridaThe purpose of this study is to find out if the combination of the drugs alpelisib and fulvestrant is better or worse than the usual approach for your type of cancer. The usual approach is defined as...
-
LAMBDA study: Longitudinal Assessment of Multidomain Brain data for early Detection of Alzheimer’s disease LAMBDA
This study is currently enrolling.Research Area: Neuroscience ResearchResearch Location: Orlando, FloridaStudy Purpose: This study will be examining changes in memory and mental function and several biological variables in aging. Examining the biology underlying memory changes could influence our...
-
NCT03671889
Assessment of Safety and Efficacy of Exablate Blood-Brain Barrier Disruption for the Treatment of Patients with Probable Alzheimer’s Disease
This study is currently enrolling.Research Area: Neuroscience ResearchResearch Location: Celebration, FloridaThe result of this study will help us determine whether blood-brain barrier disruption (BBBD) with Exablate is a safe procedure in the brains of patients with Alzheimer’s Disease. The purpose of this...
-
NCT05919511
MA-GVHD-401: A Prospective, Observational Cohort Study of Participants at Risk for Chronic Graft-Versus-Host Disease in the United States (THRIVE)
This study is currently enrolling.Research Area: Clinical Cancer ResearchResearch Location: Orlando, FloridaDescribe the clinical course and burden of cGVHD after alloSCT. Describe personal and healthcare resource utilization associated with the management of
cGVHD. Describe practice patterns and therapy... -
NCT06040099
D933GC00002: A Phase II Single-Arm Study of Durvalumab and Bevacizumab Following Transarterial Radioembolization Using Yttrium-90 Glass Microspheres (TheraSphere™) in Unresectable Hepatocellular Carcinoma
This study is currently enrolling.Research Area: Clinical Cancer ResearchResearch Location: Orlando, FloridaAstraZeneca is doing this study to learn more about durvalumab and bevacizumab given together after the TARE Y90 procedure in participants with HCC, and also to better understand HCC and associated...
-
FABULINUS: A 52-week randomized, double-blind, placebo controlled, multi-center Phase 2b study with a 52-week blinded extension assessing safety and efficacy of frexalimab, a CD40L-antagonist monoclonal antibody, for preservation of pancreatic beta-cell function in adults and adolescents with newly diagnosed type 1 diabetes on insulin therapy.
This study is currently enrolling.Research Area: Translational ResearchResearch Location: Orlando, FloridaStudy Purpose: The study is aimed to evaluate an investigational drug, frexalimab, for preservation of pancreatic beta cell function in adults and adolescents that have been newly diagnosed with Type...
-
NCT06082037
A randomized, double-blind, placebo-controlled, parallel group, Phase 3 study, followed by an open-label extension to evaluate the efficacy of oral belumosudil in adult participants with chronic ling allograft dysfunction (CLAD) following bilateral lung transplantation.
This study is currently enrolling.Research Area: Transplant ResearchThis study will be enrolling subjects who have Stage 1 or 2 chronic lung allograft dysfunction (CLAD) or “chronic lung rejection” after bilateral lung transplantation. This study is to evaluate an...
-
NCT06064877
AV-299-23-301: A Phase 3 Study of Ficlatuzumab in Combination with Cetuximab in Subjects with Recurrent or Metastatic (R/M) HPV-Negative Head and Neck Squamous Cell Carcinoma
This study is currently enrolling.Associated Conditions: ThoracicResearch Area: Clinical Cancer ResearchResearch Location: Orlando, FloridaThe main purpose of this study is to investigate the safety, effectiveness, and tolerability (whether side effects can be handled by a participant) of ficlatuzumab at two different doses when given...
-
NCT06143891
A randomized, double-blind, multicenter, Phase 3 study to evaluate efficacy and safety of belumosudil in combination with corticosteroids versus placebo in combination with corticosteroids in participants at least 12 years of age with newly diagnosed chronic graft versus host disease (cGVHD)) (ROCKnrol-1)
This study is currently enrolling.Research Area: Clinical Cancer ResearchResearch Location: Orlando, FloridaDemonstrate the superiority of belumosudil in combination with prednisone vs placebo in combination with prednisone in event free survival.
-
NCT06305767
A Phase 2, Randomized, Double-blind Study of Adjuvant V940 (mRNA-4157) + Pembrolizumab (MK-3475) vs. Placebo + Pembrolizumab for High-Risk Muscle-Invasive Urothelial Carcinoma (MIUC) Post-Radical Resection
This study is currently enrolling.Associated Conditions: Urothelial CancerResearch Area: Clinical Cancer ResearchResearch Location: Orlando, FloridaTo compare V940 plus pembrolizumab to
placebo plus pembrolizumab with respect to DFS. Hypothesis (H1): V940 plus pembrolizumab is superior to placebo plus pembrolizumab with respect to DFS as assessed...